Pizzuti Dana's Form 4 filing
Crinetics Pharmaceuticals, Inc. (CRNX) · filed Mar 22, 2024
- Accession no.
- 0001209191-24-005061
- Filed
- Mar 22, 2024
- Trade date
- Mar 20, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $664.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Pizzuti DanaCIK 0001948238 | Officer (Chief Med and Dev Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 20, 2024 | Common Stock | MOption exerciseAcquired | +4,375 | $16.89 | +$73,893.75 | 32,875 | Direct | |
| Mar 20, 2024 | Common Stock | SSaleDisposed | −4,375 | $45.89 | −$200,768.75 | 28,500 | Direct | |
| Mar 20, 2024 | Common Stock | MOption exerciseAcquired | +10,000 | $16.89 | +$168,900 | 38,500 | Direct | |
| Mar 20, 2024 | Common Stock | SSaleDisposed | −10,000 | $43.28F1 | −$432,800 | 28,500 | Direct | |
| Mar 20, 2024 | Common Stock | SSaleDisposed | −714 | $43.69 | −$31,194.66 | 27,786 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 20, 2024 | Common Stock | MOption exerciseDisposed | −4,375 | $0.00 | $0 | 201,667 | Direct | |
| Mar 20, 2024 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 191,667 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.28 per share. The range of sales prices on the transaction date was $42.70 to $43.77 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.